Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Dermatology Ophthalmology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Bacteremia

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Bacteremia

17 trials tracked for Bacteremia: 6 in phase 3 or 4 and 3 with published results. The most-cited published study has 452 citations.

17Trials tracked

6Phase 3 & 4

0Recruiting

3With published results

Phase distribution

Phase 4 3 Phase 3 3 Phase 2 5 Other / NA 6

Phase 3 Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults Completed · 452 cited
Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex Completed · 292 cited
Phase 4 Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005) Completed · 57 cited
Phase 4 Prophylactic Antimicrobial Catheter Lock Completed
Phase 4 Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults Completed
Phase 3 Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells Completed

Show 11 more trials

Phase 2 Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients Completed
Phase 2 Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection Completed
Phase 2 Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia Completed
Phase 2 Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029) Completed
Phase 2 Antibiotic "Dysbiosis" in Preterm Infants Completed
N/A Home Away From Home - Medical Outcomes Completed
N/A Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures Completed
N/A Hub Cleansing to Prevent Hub Infection Completed
N/A Safety Evaluation of Seraph® 100 to Reduce Bacteremia in Patients on Hemodialysis Completed
N/A A Cluster-randomized Cross-over Trial Evaluating the Comparative Effectiveness of Three Skin Antiseptic Interventions Completed
N/A Rapid Blood Culture Identification Panel in Pediatric Patients in Guatemala Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Bacteremia: what the trials found

Clinical outcomes for specific antibiotics in the treatment of bacteremia vary by agent. Daptomycin demonstrated clinical success rates ranging from 60.0% to 94.1% at the TOC/Safety visit ². In contrast, Ceftazidime-Avibactam showed a clinical cure rate of 59.3% in the mMITT analysis set and 78.6% in the ME analysis set at the TOC visit ³.

Safety profiles differ significantly between agents; for example, Sulbactam was associated with a higher proportion of nephrotoxicity (32%) compared to its comparator (12%) (p=0.0002) ⁶. Moxifloxacin was evaluated regarding time to fever, showing means of 9.50 and 7.69 respectively ⁷.

Recent results — preliminary, needs further review

AP-SA02 was evaluated for safety and tolerability in a Phase 2 trial; the number of participants with treatment-emergent adverse events across four groups was 17, 10, 6, and 2 (p=0.25) ¹.
Clinical improvement or response at 7 days post-antibiotic therapy for AP-SA02 was reported as 21/6 by investigators ¹ and 21/7 by the CEAC ¹.

For the clinician treating this condition

Daptomycin shows high rates of clinical success at the TOC visit, though it is associated with varying rates of CPK elevation ².
Ceftazidime-Avibactam demonstrates a clinical cure rate of approximately 60% in mMITT populations ³.
Sulbactam is associated with significantly higher rates of nephrotoxicity compared to its comparator ⁶.

AI synthesis of 5 cited trials, updated Jun 24, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.